Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 293

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 2
Chunk 293
---
 million for the three months ended September 30, 2025 compared to the three months ended September 30, 2024 was primarily due to an increase in research and development expenses of $14.3 million, which is described below under Research and Development Expenses, and an increase in selling, general and administrative expenses of $2.7 million, driven by an increase in commercial-related activities as we prepare for the potential approval of PYRUKYND® in thalassemia.

Total Operating Expenses -  Nine Months Ended September 30, 2025 vs. Nine Months Ended September 30, 2024 – The increase in total operating expenses of $58.1 million for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024 was primarily due to an increase in research and development expenses of $33.0 million which is described below under Research and Development Expenses, and an increase in selling, general and administrative expenses of $23.6 million, driven by an increase in commercial-related activities as we prepare for the potential approval of PYRUKYND® in thalassemia.

26

Research and Development Expenses

Our research and development expenses, by major program, are outlined in the table below:Three Months Ended September 30,Nine Months Ended September 30,(In thousands)2025202420252024PK activator (PYRUKYND®)$30,533 $26,829 $81,663 $80,833 Novel PK activator (tebapivat)8,498 3,768 21,738 10,151 In-process research and development— — 10,000 — Other research and platform programs6,668 4,316 15,506 15,271 Total direct research and development expenses45,699 34,913 128,907 106,255 Compensation and related expenses30,299 28,115 90,883 83,225 Facilities and IT related expenses & other10,798 9,427 31,689 28,996 Total indirect research and development expenses41,097 37,542 122,572 112,221 Total research and development expense$86,796 $72,455 $251,479 $218,476 

Total Research and Development Expenses - Three Months Ended September 30, 2025 vs.